Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Paul Bergmans"'
Autor:
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatríz Joven-Ibáñez, Tatiana V. Korotaeva, Frederic Lavie, Wim Noël, Michael T. Nurmohamed, Petros P. Sfikakis, Mohamed Sharaf, Elke Theander, Josef S. Smolen
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-14 (2023)
Abstract Background To evaluate the real-world effect of the IL-12/23 inhibitor ustekinumab or of a tumour necrosis factor inhibitor (TNFi) on patient-reported outcomes (PRO) and their association with effectiveness endpoints in psoriatic arthritis (
Externí odkaz:
https://doaj.org/article/cb91ef694a0f432685e67e35bc6d52c9
Autor:
Laure Gossec, Elke Theander, Soumya D. Chakravarty, Paul Bergmans, Frederic Lavie, Wim Noël, Mohamed Sharaf, Stefan Siebert, Josef S. Smolen
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-9 (2023)
Abstract Background This post-hoc analysis of PsABio (NCT02627768) evaluated safety, effectiveness and treatment persistence in patients
Externí odkaz:
https://doaj.org/article/ea108c668aa748ff96589e82342b3aa6
Autor:
Rebekka Lencer, Maria Paz Garcia-Portilla, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller, Katalin Pungor
Publikováno v:
Comprehensive Psychiatry, Vol 107, Iss , Pp 152233- (2021)
Rationale: Reducing the frequency of long-acting injectable antipsychotic medication may reduce carer burden. Objectives: To evaluate the impact of reduced frequency of long-acting injectable antipsychotic medication on carer burden in stable patient
Externí odkaz:
https://doaj.org/article/51ab9250a21847269b9ad3fa8a1bb76a
Autor:
Katalin Pungor, Vasilis P. Bozikas, Robin Emsley, Pierre-Michel Llorca, Srihari Gopal, Maju Mathews, Annette Wooller, Paul Bergmans
Publikováno v:
Therapeutic Advances in Psychopharmacology, Vol 10 (2020)
Background: Paliperidone palmitate 3-monthly (PP3M) is a second-generation, long-acting injectable antipsychotic formulation indicated for the maintenance treatment of adults with schizophrenia first stabilized with paliperidone palmitate 1-monthly (
Externí odkaz:
https://doaj.org/article/b3fa4be270c14f9fa42165c0eeb276ea
Autor:
Maria Paz Garcia-Portilla, Pierre-Michel Llorca, Giuseppe Maina, Vasilis P. Bozikas, Halise Devrimci-Ozguven, Sung-Wan Kim, Paul Bergmans, Irina Usankova, Katalin Pungor
Publikováno v:
Therapeutic Advances in Psychopharmacology, Vol 10 (2020)
Background: Paliperidone palmitate 3-monthly (PP3M) formulation is a long-acting, injectable antipsychotic treatment approved in many countries worldwide for the maintenance treatment of adult patients with schizophrenia. This single-arm, open-label,
Externí odkaz:
https://doaj.org/article/9b1afb3a4e6044e6b005a52cf7c7ab9a
Autor:
Arno W R Van Kuijk, Mike T Nurmohamed, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibáñez, T V Korotaeva, Frederic Lavie, Mohammed Sharaf, Wim Noël, Elke Theander, Josef S Smolen, Laure Gossec, Irene E van der Horst-Bruinsma
Publikováno v:
Rheumatology.
Objective Investigate effects of gender on disease characteristics and treatment impact in patients with psoriatic arthritis (PsA). Methods PsABio is a non-interventional European study in patients with PsA starting a biological disease-modifying ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb7fa68d3ee82bd85ad6a068accbe73
https://doi.org/10.1093/rheumatology/kead089
https://doi.org/10.1093/rheumatology/kead089
Autor:
Elisa, Gremese, Francesco, Ciccia, Carlo, Selmi, Giovanna, Cuomo, Rosario, Foti, Marco, Matucci-Cerinic, Fabrizio, Conti, Enrico, Fusaro, Giuliana, Guggino, Florenzo, Iannone, Andrea, Delle Sedie, Roberto, Perricone, Luca, Idolazzi, Paolo, Moscato, Elke, Theander, Wim, Noël, Paul, Bergmans, Silvia, Marelli, Laure, Gossec, Josef S, Smolen, Carlotta, Galeone
Publikováno v:
Clinical and experimental rheumatology.
To compare real-world persistence, effectiveness and tolerability of ustekinumab versus TNF inhibitors (TNFi) in psoriatic arthritis (PsA).One-year data from Italian subjects enrolled in the PsABio study (PsA patients receiving 1st- to 3rd-line treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3ac34daf38d32cbff573ff693ef18f4
https://pubmed.ncbi.nlm.nih.gov/36226614
https://pubmed.ncbi.nlm.nih.gov/36226614
Autor:
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatríz Joven-Ibáñez, Tatiana V Korotaeva, Frederic Lavie, Wim Noël, Michael T Nurmohamed, Petros P Sfikakis, Elke Theander, Josef S Smolen
Publikováno v:
Gossec, L, Siebert, S, Bergmans, P, de Vlam, K, Gremese, E, Joven-Ibáñez, B, Korotaeva, T V, Lavie, F, Noël, W, Nurmohamed, M T, Sfikakis, P P, Theander, E & Smolen, J S 2022, ' Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis : 1-year results from the real-world PsABio Study ', Annals of the Rheumatic Diseases, vol. 81, no. 6, 221640, pp. 823-830 . https://doi.org/10.1136/annrheumdis-2021-221640
Annals of the Rheumatic Diseases, 81(6):221640, 823-830. BMJ Publishing Group
Annals of the Rheumatic Diseases, 81(6):221640, 823-830. BMJ Publishing Group
ObjectiveWe evaluated real-world treatment persistence and effectiveness at 1 year following initiation of IL-12/23 inhibitor ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis (PsA).MethodsPsABio (NCT02627768), a prospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61271cc926779bf70df67ef831d26727
https://lirias.kuleuven.be/handle/20.500.12942/707337
https://lirias.kuleuven.be/handle/20.500.12942/707337
Autor:
Dennis Muris, Max Molenaers, Trang Nguyen, Paul Bergmans, Bernadette van Acker, Mariëlle Krekels, J.W.L. Cals
Publikováno v:
Huisarts en Wetenschap, 65(10), 14-17. Bohn Stafleu van Loghum
Omdat huisartsen steeds meer diagnostiek aanvragen, is zinnig en efficiënt aanvraaggedrag een speerpunt van beleid. Wij onderzochten voor 22 laboratoriumtests of huisartsen minder geneigd waren die test aan te vragen als ze de prijs in beeld kregen.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6e558685898a918c41166342b5cfbcb
https://cris.maastrichtuniversity.nl/en/publications/9569ad13-5c5d-4b39-8138-8e98fff710ee
https://cris.maastrichtuniversity.nl/en/publications/9569ad13-5c5d-4b39-8138-8e98fff710ee
Autor:
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibáñez, Tatiana V Korotaeva, Frederic Lavie, Wim Noël, Michael T Nurmohamed, Petros P Sfikakis, Mohamed Sharaf, Elke Theander, Josef S Smolen
Publikováno v:
Annals of the Rheumatic Diseases. BMJ Publishing Group
Gossec, L, Siebert, S, Bergmans, P, de Vlam, K, Gremese, E, Joven-Ibáñez, B, Korotaeva, T V, Lavie, F, Noël, W, Nurmohamed, M T, Sfikakis, P P, Sharaf, M, Theander, E & Smolen, J S 2022, ' Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis : final 3-year results from the PsABio real-world study ', Annals of the Rheumatic Diseases . https://doi.org/10.1136/ard-2022-222879, https://doi.org/10.1136/ard-2022-222879
Gossec, L, Siebert, S, Bergmans, P, de Vlam, K, Gremese, E, Joven-Ibáñez, B, Korotaeva, T V, Lavie, F, Noël, W, Nurmohamed, M T, Sfikakis, P P, Sharaf, M, Theander, E & Smolen, J S 2022, ' Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis : final 3-year results from the PsABio real-world study ', Annals of the Rheumatic Diseases . https://doi.org/10.1136/ard-2022-222879, https://doi.org/10.1136/ard-2022-222879
ObjectivesTo evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years.MethodsPsABio (NCT02627768), a prospective, observational study, f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::118a22a0288da95827074b2dcdf4c5bc
https://doi.org/10.1136/ard-2022-222879
https://doi.org/10.1136/ard-2022-222879